[1] Calleja JL, Delgado S, del Val A, Hervás A, Larraona JL, Terán Á, et al. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia[J]. International Journal of Colorectal Disease, 2016, 31(3):543-551.
[2] Dongze Hou, Jinsong Dai, Zhibo Deng, Denggao Yan. Effects of hemoglobin level and perioperative blood transfusion on prognosis of patients with clon cancer[J]. Modern Oncology, 2018, 26(07):1070-1074.
[3] Ceanga AI, Ceanga M, Eveslage M, Herrmann E, Fischer D, Haferkamp A, et al. Preoperative anemia and extensive transfusion during stay-in-hospital are critical for patient's mortality: A retrospective multicenter cohort study of oncological patients undergoing radical cystectomy[J]. Transfusion and apheresis science: official journal of the World Apheresis Association: official journal of the European Society for Haemapheresis, 2018, 57(6):739-745.
[4] Ness PM, Triulzi DJ, Carson JL. Adverse Effects of Red-Cell Transfusion[J]. New England Journal of Medicine, 2018, 378(1):97.
[5] Aquina CT, Blumberg N, Becerra AZ, Boscoe FP, Schymura MJ, Noyes K, et al. Association Among Blood Transfusion, Sepsis, and Decreased Long-term Survival After Colon Cancer Resection[J]. Annals of Surgery, 2017, 266(2):311-317.
[6] Hart S, Cserti-Gazdewich CM, McCluskey SA. Red cell transfusion and the immune system[J]. Anaesthesia, 2015, 70(s1):38-45.
[7] Xiaowen Liu, Mingze Ma, Hua Huang, Yanong Wang. Effect of perioperative blood transfusion on prognosis of patients with gastric cancer: a retrospective analysis of a single center database[J]. BMC Cancer, 2018, 18(1):649.
[8] Qianyun Pang, Ran An, Hongliang Liu. Perioperative transfusion and the prognosis of colorectal cancer surgery: a systematic review and meta-analysis[J]. World Journal of Surgical Oncology, 2019, 17(1):7.
[9] Cata JP, Wang H, Gottumukkala V, Reuben J, Sessler DI. Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions[J]. British Journal of Anaesthesia, 2013, 110(5):690-701.
[10] Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression[J]. Immunity, 2009, 30(5):636-645.
[11] Pereira LMS, Gomes STM, Ishak R, Vallinoto ACR. Regulatory T Cell and Forkhead Box Protein 3 as Modulators of Immune Homeostasis[J]. Frontiers in Immunology, 2017, 8:605.
[12] Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: Forkhead box protein 3 mutations and lack of regulatory T cells[J]. Journal of Allergy and Clinical Immunology, 2007, 120(4):744-750.
[13] Jinhui Tao, Miao Cheng, Jiangping Tang, Qin Liu, Fan Pan, Xiangpei Li. Foxp3, Regulatory T Cell, and Autoimmune Diseases[J]. Inflammation, 2017, 40(1):328-339.
[14] Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells[J]. Nature Immunology, 2003, 4(4):330-336.
[15 ]Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells[J]. Journal of Experimental Medicine, 2006, 203(7):1701-1711.
[16] Watkins WM. The ABO blood group system: historical background[J]. Transfusion Medicine, 2010, 11(4):243-265.
[17] Zhiwei Wang, Lei Liu, Jun Ji, Jianian Zhang, Min Yan, Jun Zhang, et al. ABO Blood Group System and Gastric Cancer: A Case-Control Study and Meta-Analysis[J]. International Journal of Molecular Sciences, 2012, 13(10):13308-13321.
[18] Iodice S, Maisonneuve P, Botteri E, Sandri MT, Lowenfels AB. ABO blood group and cancer[J]. European Journal of Cancer, 2010, 46(18):3345-3350.
[19] Bailin Zhang, Na He, Yubei Huang, Fengju Song, Kexin Chen. ABO Blood Groups and Risk of Cancer: a Systematic Review and Meta-analysis[J]. Asian Pacific journal of cancer prevention: APJCP, 2014, 15(11):4643-4650.
[20] Franchini M, Lippi G. The intriguing relationship between the ABO blood group, cardiovascular disease, and cancer[J]. BMC Medicine, 2015, 13(1):7.
[21] Fagherazzi G, Gusto G, Clavel-Chapelon F, Balkau B, Bonnet F. ABO and Rhesus blood groups and risk of type 2 diabetes: evidence from the large E3N cohort study[J]. Diabetologia, 2015, 58(3):519-522.
[22] Jianshe Yu, Yaying Xie, Yiri Du, Haixia Shi, Dongmei Chen, Zhiqiang Han. Effects of ABO blood group factors on erythrocyte suspension transfusion reactions[J]. Chinese Journal of Anesthesiology, 2015, (12):1425-1427.
[23] Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*[J]. Anesthesiology, 2015, 122(2):241-275.
[24] Technical specifications for clinical blood transfusion [J]. Chinese Hospital, 2000, 4 (6):1-11.
[25] Yuan JS, Reed A, Chen F, Stewart CN Jr. Statistical analysis of real-time PCR data[J]. BMC Bioinformatics, 2006, 7(1):85.
[26] Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method[J]. Methods, 2001, 25(4):402-408.
[27] Yiting Geng, Hui Wang, Changqing Lu, Qing Li, Bin Xu, Jingting Jiang, et al. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+Tregs in gastric cancer and its clinical significance[J]. International Journal of Clinical Oncology, 2015, 20(2):273-281.
[28] Ganapathi SK, Beggs AD, Hodgson SV, Kumar D. Expression and DNA methylation of TNF, IFNG and FOXP3 in colorectal cancer and their prognostic significance[J]. British Journal of Cancer, 2014, 111(8):1581-1589.
[29] Wolf D, Sopper S, Pircher A, Gastl G, Wolf AM. Treg(s) in Cancer: Friends or Foe?[J]. Journal of Cellular Physiology, 2015, 230(11):2598-2605.
[30] Shevach EM, Thornton AM. tTregs, pTregs, and iTregs: similarities and differences[J]. Immunological Reviews, 2014, 259(1):88-102.
[31] Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor foxp3[J]. Journal of Experimental Medicine, 2003, 198(12):1875-1886.
[32] Bower MR, Ellis SF, Scoggins CR, McMasters KM, Martin RC. Phase II comparison study of intraoperative autotransfusion for major oncologic procedures[J]. Annals of Surgical Oncology, 2011, 18(1):166-173.
[33] Amico F, Briggs G, Balogh ZJ. Transfused trauma patients have better outcomes when transfused with blood components from young donors[J]. Medical hypotheses, 2019, 122:141-146.
[34] Mouw TJ, Lu J, Woody-Fowler M, Ashcraft J, Valentino J, DiPasco P, et al. Morbidity and mortality of synchronous hepatectomy with cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)[J]. Journal of Gastrointestinal Oncology, 2018, 9(5):828-832.
[35] Landers DF, Hill GE, Wong KC, Fox IJ. Blood Transfusion-Induced Immunomodulation[J]. Anesthesia and Analgesia, 1996, 82(1):187-204.
[36] Youssef LA, Spitalnik SL. Transfusion-related immunomodulation: a reappraisal.[J]. Current Opinion in Hematology, 2017, 24(6):551-557.
[37] Sahu S, Hemlata H, Verma A. Adverse events related to blood transfusion[J]. Indian Journal of Anaesthesia, 2014, 58(5):543-551.
[38] Cata JP, Gottumukkala V. Blood transfusion practices in cancer surgery[J]. Indian Journal of Anaesthesia, 2014, 58(5):637-642.
[39] Danesh A, Inglis HC, Jackman RP, Wu S, Deng X, Muench MO, et al. Exosomes from red blood cell units bind to monocytes and induce proinflammatory cytokines, boosting T-cell responses in vitro[J]. Blood, 2013, 123(5):687-696.
[40] Greenwell P. Blood group antigens: molecules seeking a function?[J]. Glycoconjugate Journal, 1997, 14(2):159-173.